A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-03-24
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-08 (study day 124); relationship: not assessed
mild
assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-07 (study day 154); relationship: N
mild
assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-08-17 (study day 498); relationship: not assessed
Data queries
No data queries.